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PENILAIAN ANTI-CARBAMYLATED PROTEIN ANTIBODI SEBAGAI 
PENANDABIO YANG BERPOTENSI MEMBANTU DALAM 
PENDIAGNOSAN RHEUMATOID ARTHRITIS SERTA KAITANNYA 
DENGAN AKTIVITI PENYAKIT 
 
 
ABSTRAK   
 
 
Rheumatoid arthritis (RA) merupakan penyakit radang reumatik yang 
dicirikan oleh kehadiran autoantibodi. Kajian ini bertujuan untuk mengukur nilai 
sensitiviti dan spesifikasi protein anti-carbamylated (anti-CarP) antibodi dalam 
pesakit RA yang dikaitkan dengan faktor rheumatoid (RF), anti-cyclic citrullinated 
peptide (anti-CCP) antibodi, C-reactive protein (CRP ) dan juga untuk menentukan 
perkaitan mereka dengan 28-skor aktiviti penyakit (DAS28) dan skor soal selidik 
penilaian kesihatan (HAQ). Kajian ini melibatkan 105 pesakit RA (57 pesakit RF-
negatif dan 48 RF-positif) yang dijalankan di Hospital Universiti Sains Malaysia 
(HUSM) mulai Januari 2015 sehingga bulan Februari 2016. Lima puluh individu 
sihat telah terlibat. CRP, RF, antibodi anti-CCP dan antibodi anti-CarP telah diukur. 
HAQ telah diagihkan kepada setiap peserta kajian. DAS28 bagi 105 pesakit RA telah 
diukur. Tahap antibodi anti-CarP telah meningkat secara jelas dalam pesakit RA 
berbanding dalam individu sihat (p=0.042). Sensitiviti dan spesifikasi antibodi anti-
CarP bagi pesakit RA masing-masing adalah 42% dan 78%. Kehadiran antibodi anti-
CarP dikaitkan secara jelas dengan RF (p=0.019) dan keputusan HAQ (p= 0.010). 
Walau bagaimanapun, tidak ada perkaitan yang jelas antara antibodi anti-CarP 
xv 
 
dengan anti-CCP dan CRP (masing-masing adalah p=0,564 dan p=0.075). Tambahan 
pula, perkaitan yang jelas antara antibodi anti-CarP dengan DAS28 tidak dijumpai 
(p=0.165). Kajian ini memberikan bukti lanjut bahawa tahap antibodi anti-CarP 
adalah tinggi secara jelas pada pesakit RA. Di samping itu, kajian ini menunjukkan 
bahawa pesakit RA yang mempunyai positif anti-CarP lebih cenderung untuk 
menunjukkan peningkatan dalam ketidakupayaan berbanding pesakit RA yang 
mempunyai negatif anti-CarP. Oleh itu, antibodi anti-CarP mempunyai potensi untuk 
dijadikan sebagai penandabio bagi membantu dalam diagnosis dan prognosis RA. 
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EVALUATION OF ANTI-CARBAMYLATED PROTEIN ANTIBODIES AS A 
POTENTIAL BIOMARKER IN ASSISTING THE DIAGNOSIS OF 
RHEUMATOID ARTHRITIS AND ITS CORRELATION WITH DISEASE 
ACTIVITY 
 
 
ABSTRACT 
 
 
Rheumatoid arthritis (RA) is an inflammatory rheumatic disease 
characterized by the presence of autoantibodies. This study aims to determine the 
sensitivity and specificity of anti-carbamylated protein (anti-CarP) antibodies in 
rheumatoid arthritis (RA) patients in relation to rheumatoid factor (RF), anti-cyclic 
citrullinated peptide (anti-CCP) antibodies, C-reactive protein (CRP) as well as to 
determine their association with disease activity score-28 (DAS28) and health 
assessment questionnaire (HAQ) score. This study included 105 RA patients (48 RF-
positive and 57 RF-negative patients) conducted at Hospital Universiti Sains 
Malaysia (HUSM) from January 2015 until February 2016. Fifty healthy controls 
(HCs) were included. CRP, RF, anti-CCP and anti-CarP antibodies were measured. 
HAQ was administered to each of the study participants. DAS28 of the 105 RA 
patients was measured. The level of anti-CarP antibodies was significantly increased 
in the RA patients compared to that in the HCs (p=0.042). The sensitivity and 
specificity of anti-CarP antibodies in RA patients were 42% and 78%, respectively. 
The presence of anti-CarP antibodies was significantly associated with RF (p=0.019) 
and the HAQ results (p=0.010). However, there was no significant association of 
xvii 
 
anti-CarP antibodies with anti-CCP antibodies and CRP (p=0.564 and p=0.075, 
respectively). Furthermore, a significant association between anti-CarP antibodies 
with DAS28 was not found (p=0.165). This study provides further evidence that the 
level of anti-CarP antibodies is significantly elevated in RA patients. In addition, this 
study showed that anti-CarP-positive RA patients more likely to demonstrate 
increased disability compared to anti-CarP-negative RA patients. Therefore, anti-
CarP antibodies have a potential to be further develop as a biomarker to aid in the 
diagnosis and prognosis of RA. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
1.1 HUMAN IMMUNE SYSTEM 
The immune system is made up of different groups of cells, tissues, as well as 
organs that work together to protect the body against the invasion by the pathogens. 
Pathogens can be divided into four kinds; bacteria, viruses, fungi and parasites 
(Parham, 2014). Natural defence mechanism has the ability to differentiate between 
the body’s own cells and foreign cells. The immune system is classified into innate 
immunity and adaptive immunity.  
 
1.1.1   Innate immunity 
The innate immunity provides the body’s early line of defence and aims to 
prevent the entry of pathogenic substances (Abbas et al., 2014). Innate immunity 
consisting of various components including skin, mucous membrane, antimicrobial 
substance, phagocytic cells, dendritic cells (DCs), natural killer (NK) cells and blood 
proteins (Abbas et al., 2014). Innate immunity is effective to protect the body from 
infection, however, many pathogens are able to overcome the innate immunity. It is 
known that the skin immune responses provide effective host defence against many 
2 
 
pathogens, however, it also contributes to inflammatory skin diseases. It has been 
described that several components including pathogens contribute to complex skin 
immune reactions (Yazdi et al., 2016). Thus, more effective defence systems of 
adaptive immunity are required to successfully fight against the pathogenic microbes. 
 
1.1.2    Adaptive immunity 
The adaptive immunity develops as a response to infection which improves 
with each successive exposure to particular pathogens. The typical feature of 
adaptive immunity is the ability to differentiate between substances, called 
specificity and the ability to provide a quick and powerful response to repeated 
exposures of the similar pathogen, known as memory (Abbas et al., 2014).  
 
The adaptive immunity refers to the defence mechanisms characterized by T cell 
specific for an antigen from the invading pathogens, and by B cells which secreted 
antibodies that bind to these antigens for their elimination. The successful adaptive 
immune response in eliminating infection provides long-lasting protective immunity 
against the particular pathogens. 
 
1.1.3    Autoimmunity and autoimmune diseases 
Autoimmunity is a state in which the immune system exhibits immunological 
responses against its own healthy cells and tissues. Over the year, a significant 
increase has been observed in the incidence of autoimmune disease worldwide. 
Immune tolerance is important because it plays a role in preventing the immune 
system from recognizing self-proteins. The innate and adaptive immunity shown to 
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be responsible for the inhibition or development of autoimmune disease (Vojdani, 
2014). 
 
It has been shown that the loss of the immunological tolerance directed to self-
antigens could lead to the development of autoimmunity (Conigliaro et al., 2016). 
Several genes are known to contribute to the loss of tolerance, in which the gene 
factors could involve in antigen presentation, lymphocyte differentiation as well as 
encodes for T and B cells receptors (Gianchecchi and Fierabracci, 2015). 
 
Autoimmunity is characterized by the presence of autoantibodies in susceptible 
individuals (McInnes and Schett, 2007). A previous study demonstrated that the 
periodontal pathogen, Porphyromonas gingivalis able to citrullinate proteins which 
provide a potential mechanism for breaking of self-tolerance to citrullinated proteins 
in rheumatoid arthritis (RA) (Wegner et al., 2010).  
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1.2      RHEUMATOID ARTHRITIS (RA) 
Rheumatoid arthritis (RA) is a chronic disease characterized by the 
destruction of synovial joint with erosive cartilage and bone damage (Brink et al., 
2015; Jeffery, 2014). Increased infiltration in synovial tissue by mononuclear cells, 
especially T cells and macrophages, and hyperplasia of the synovial sublining are 
typical features of RA (Firestein et al., 2012). The abnormal regulation of adaptive 
immunity precedes the onset of clinical symptoms, while the repeated initiation of 
innate immunity can contribute to the loss of tolerance in RA (Bartok and Firestein, 
2010). 
 
1.2.1    Incidence and prevalence    
RA affects 0.5% - 1.0% of the adult population worldwide, being women two 
to four times more likely to be affected than men (Jeffery, 2014). Of 291 conditions, 
RA was ranked as the 42nd highest contributor to global disability in the Burden of 
Disease 2010 study (Cross et al., 2014) indicating that RA associated with severe 
implications for the affected individuals. It is reported that the incidence of RA is 20-
45/100,000 in Asians (Alamanos and Drosos, 2005), 10-50/100,000 in Latin 
American (Gonzalez et al., 2008) and 10-50/100,000 in Middle east populations 
(Al‐Mutairi et al., 2010). 
 
1.2.2    Risk factors 
RA remains uncertain in the description of their exact causes and pathogenic 
mechanisms, but genetic and environmental influences clearly participate (Smolen 
and Steiner, 2003). Over the decades, a few environmental risk factors such as 
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smoking, socioeconomic factors, hormonal factors, ethnicity and infectious agents 
are known to contribute to the development of RA (Alamanos and Drosos, 2005). 
 
A previous study demonstrates a  disease concordance rates of 15% - 30% among 
monozygotic twins and concordance rates of 5% among dizygotic twins (MacGregor 
et al., 2000). The HLA region has an impact on the genetic risk and may account for 
RA susceptibility in multiple ethnic groups (El-Saadany et al., 2016). The HLA-
DRB1 alleles demonstrated to be associated with disease severity in RA (Weyand et 
al., 1992). It is reported that most of the RA patients carry the HLA-DRB1*04 alleles 
(Smolen et al., 2007). Furthermore, the patients that express two HLA-DRB1*04 
alleles have a greater risk for nodular disease, major organ failure and joint surgery 
(Weyand et al., 1992). 
 
Several infectious agents, including Epstein-Barr virus (EBV), proteus, and 
mycoplasma are associated with RA (Silman and Pearson, 2002). Over the last 
decades, EBV has been described as the potential risk factor for RA with the growing 
evidence supporting this. The present of EBV in the synovial fluid of RA patients 
indicate that it could contribute to the development of RA (Takeda et al., 2000). 
 
Bronchopulmonary infection in RA patients is associated with severe functional 
disability and the prevalence is greater compared to non-RA patients (Arshad and 
Rashid, 2008). It is demonstrated that periodontal pathogen known as 
Aggregatibacter actinomycetemcomitans induces hypercitrullination of proteins 
observed in the joints of RA patients indicating that periodontal infection is 
associated with RA pathogenesis (Konig et al., 2016a). 
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1.2.3    Immunopathogenesis 
It is known that the pathogenesis of RA is characterized by the interaction of 
different inflammatory cells and cells contain in the joint which communicates via a 
network of proteins termed as cytokines. It is known that under normal condition, 
there is a balance of pro-inflammatory cytokines and anti-inflammatory cytokines. 
However, the balance shifts toward the production of more pro-inflammatory 
cytokines in RA. 
 
The pathogenesis of RA involves the activation of the innate immunity by 
stimulating dendritic cells (DCs) (Figure 1.1). DCs could contribute to the 
pathogenesis of RA in several ways. A previous study reported that DCs trigger the 
initiation and perpetuation of RA by the antigen presentation to T cells  (Leung et al., 
2002). In addition, these DCs could mediate the activation of the infiltrating T cells 
which is sufficient for the development of the autoantibody and chronic 
inflammation (Lutzky et al., 2007). 
 
Moreover, DCs are enriched in both the synovial tissue and synovial fluid of joints 
affected by RA (Thomas and Quinn, 1996). In addition, DCs together with the 
synoviocytes and macrophages producing the innate inflammatory mediators, in 
which these mediators mediate the inflammatory condition in RA (Cavanagh et al., 
2005; Leung et al., 2002).  
 
The macrophage is a  dominant mediator of synovial inflammation in RA. Clinically 
effective biologic agents are needed in order to reduce macrophage infiltration in the 
synovial membrane (Haringman et al., 2005). Macrophages play a role in cytokine 
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production, including tumour necrosis factor-α (TNF-α), interleukin-1, 6, 12, 15, 18 
and 23. It is also involved in phagocytosis and antigen presentation (McInnes and 
Schett, 2011). TNF-α act through activation of cytokine and chemokine and 
induction of pain (Feldmann et al., 1996; Hess et al., 2011). Furthermore, interleukin 
6 (IL-6) plays a role through activation of leukocyte and production of autoantibody 
(McInnes and Schett, 2011). 
 
It is known that chemokines responsible for the migration of the inflammatory 
leukocytes including neutrophils and monocytes into the synovium and play a role in 
arthritic vessel formation termed as angiogenesis (Szekanecz et al., 2009). This 
evidence indicate that chemokines and chemokine receptors play a crucial role in the 
inflammatory process of RA and therefore identification of inhibitors which targeted 
the chemokines should be vigorously initiated for the development of new 
therapeutic agents. 
 
Synovial hyperplasia is present due to the increased number of macrophages and 
FLS in the synovial lining layer. Synoviocytes are responsible for several functions 
under normal conditions including the formation of synovial fluid components, 
however, the FLS present in the synovial intimal lining can trigger the production of 
cytokine, leading to the perpetuation of inflammation and cartilage destruction 
(Bartok and Firestein, 2010). The altered function of synoviocytes in RA could be 
due to the abnormal regulation of molecular mechanisms influenced by the presence 
of somatic mutations in major genes (Firestein, 2003). It has been shown that the 
mutated genes such as the p53 tumour suppressor are present in synovial tissue and 
synoviocytes of RA patients (Inazuka et al., 2000). 
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T-cells upregulation is associated with the production of various lymphokines, in 
which these lymphokines stimulate the T-cells to induce macrophages, B cells, 
fibroblasts and osteoclasts activation. B lymphocytes produce many cell-surface 
molecules, including immunoglobulin (Ig), and differentiation antigens (CD20 and 
CD22). B lymphocytes differentiate into plasma cells that produce antibodies, 
including autoantibodies such as rheumatoid factor (RF) and citrullinated proteins 
(Zwerina et al., 2005).  
 
 
 
 
 
 
 
Figure 1.1: Multiple pathogenic mechanisms in RA. This model implicating that 
innate immunity is activated by triggering the immune cells including dendritic cells 
(DCs), macrophages, fibroblasts and mast cells. After the migration of immune cells 
into the synovium occurs, the adaptive immune response will present in susceptible 
individuals. The migration of DCs into lymph nodes bias T cells to a T helper 1 
phenotype. RANKL responsible for the activation of osteoclast that mediates bone 
resorption, while synoviocytes can invade cartilage.  Adapted from (Firestein, 2003) 
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1.2.4    Clinical signs and symptoms 
 
1.2.4 (a) Articular manifestation 
RA is characterized by symmetrical polyarthritis that affects the small and 
large joints (Reid and Miller, 2008) in which hand, feet, and wrists being most 
commonly affected (Cojocaru et al., 2010). One of the features of RA is the presence 
of morning stiffness in and around the joints (Grassi et al., 1998). Most of RA 
patients presented with bilateral pain and stiffness in the joints of the hand (Wahab et 
al., 2013). 
 
It is found that most of the RA patients presented with more cases of bilateral 
involvement compared to the unilateral involvement of the shoulder and it is shown 
that the bilateral involvement is linked to the higher disease activity (Elbinoune et 
al., 2016). The pathological features of RA are the occurrence of increased thickness 
of the synovial lining layer comprising of numerous macrophages and fibroblast-like 
synoviocytes (FLS) (Figure 1.2). However, a healthy joint presented with the small 
volume of synovium and a thin synovial lining layer containing FLS.   
 
 
10 
 
 
Figure 1.2: Comparison of normal joint and joint affected by RA. Adapted from 
(Hawtree et al., 2013) 
 
1.2.4 (b) Extra-articular manifestation 
In addition to the joint involvement, RA has been shown to be associated with 
the development of extra-articular manifestations (Turesson et al., 2007). These 
extra-articular RA (ExRA) manifestations including rheumatoid nodules, rheumatoid 
vasculitis, anemia, cardiovascular disease, cutaneous and pleuropulmonary 
(Hochberg et al., 2008; Yildirim et al., 2004). Several non-articular muscular 
structures including tendons, ligaments, and fascia can be affected by RA (Mielants 
and Van den Bosch, 2009).  
 
ExRA is associated with premature mortality in RA patients (Bongartz et al., 2007). 
RA-related mortality mostly occurs at age ≥50 years in 90% of 3955 cases (Pinheiro 
et al., 2015). Furthermore, the rheumatoid meningoencephalitis that rarely occurs in 
RA could develop before the onset of clinical signs (Shibahara et al., 2016). 
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Several predictors of ExRA has been shown including serological, clinical and 
genetic factors (Turesson and Jacobsson, 2004). The presence of RF shown to be 
higher in patients diagnosed with ExRA compared to non-ExRA patients, and it is 
known that patients developed ExRA are associated with higher swollen joint counts 
(Turesson et al., 2007). RA patients presented with ExRA should be provided with 
aggressive and early treatment (Young and Koduri, 2007). An improved 
understanding of the RA pathogenesis and the new treatment strategies are beneficial 
for RA patients with extra-articular manifestations (Lindqvist et al., 2002). 
 
1.2.5    American College of Rheumatology (ACR) criteria 
The 2010 American College of Rheumatology (ACR) classification criteria is 
useful for the diagnosis of RA in which scores can be obtained from joint 
involvement, serological markers, acute-phase reactants and duration of symptoms 
(Aletaha et al., 2010). Classification as having the definite RA is mainly based on the 
presence of synovitis in at least 1 joint and accumulation of a score of  ≥ 6/10 from 
the four categories (Table 1.1).  
 
The large joints include the shoulders, knees, elbows, and ankles, while the small 
joints include the metacarpophalangeal (MCP), metatarsophalangeal (MTP), 
proximal interphalangeal (PIP), thumb interphalangeal joint and wrists. Duration of 
symptoms refers to the duration of signs or symptoms of synovitis including pain, 
swelling and tenderness of joints reported by the patients. 
 
 
 
12 
 
Table 1.1: The 2010 ACR classification criteria for RA. Adapted from (Aletaha et 
al., 2010) 
 
Target population: patients who (i) have at least 1 joint with clinical synovitis and (ii) 
with the synovitis not better explained by another disease. 
A.Joint involvement (tender/swollen) Score 
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint) 5 
B. Serology  
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms 
<6 weeks 0 
≥6 weeks 1 
Add score of categories A-D: A cumulative score of  ≥6/10 is needed for the 
classification of a patient as having definite RA 
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1.2.6    Serological markers 
RA patients are a heterogenous group with well-known differences in severity 
of disease (Agrawal et al., 2007). This heterogenous group can be subdivided by the 
occurrence of autoantibodies in the sera of RA patients (Boissier et al., 2012). 
Autoantibody-positive and negative RA patients were demonstrated to have a 
different genetic background, disease development processes and responses to 
treatments (Huizinga and Pincus, 2010).  
 
Combinations of autoantibodies and genetic markers can be highly predictive for the 
development of RA (Nielen et al., 2004; Rantapää‐Dahlqvist et al., 2003). These 
findings have led to an increased investigation focus on the autoantibodies in order to 
establish better biomarker in the diagnosis of RA.  
 
There is so far no single diagnostic test to confirm RA. The major basis for the 
diagnosis is the clinical examination and laboratory tests including rheumatoid factor 
(RF), anti-cyclic citrullinated peptide (anti-CCP), C-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR). 
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1.2.6 (a)    Rheumatoid Factor (RF) 
The first autoantibody in RA, rheumatoid factor (RF) was described by Emil 
Waaler in 1940 (Waaler, 1940). RF is responsible for the initiation of an immune 
complex, in which the pathogenic role of RF in RA has been subsequently described 
by Zvaifler in 1972 (Zvaifler, 1972). RF is useful in the diagnosis of RA, which has 
been included in the ACR classification criteria for RA (Aletaha et al., 2010).  
 
RF can be a prognostic tool for RA, which associated with the presence of more 
erosive disease, rapid disease progression, and worse outcome (Steiner and Smolen, 
2002). RF recognizes the Fc portion of the patient’s own immunoglobulin (Ig)G 
molecule (Sutton et al., 2000). Their presence is determined by agglutination assays, 
nephelometry, or ELISA tests (Schellekens et al., 1998).  
 
IgM-RF is the most frequent type of RF found in RA which presents in 60–80% of 
established cases of RA (Nell et al., 2005). Although IgG-RF and IgM-RF are the 
most abundant in RA, IgE-RF has been demonstrated to be present in RA especially 
in patients with extra-articular manifestations whereas IgA-RF is also produced in 
RA including patients who are seronegative as determined by standard clinical tests 
that primarily detect IgM-RF (Firestein et al., 2012). However, individuals with more 
than one RF isotypes is associated with the increased incidence of RA (Jónsson et 
al., 2000). 
 
The RF produced in healthy individuals differ from those produced by RA patients. 
RF in healthy individuals are polyreactive and are of low affinity (Børretzen et al., 
1997) whereas RF in RA patients is monoreactive that are of relatively high affinity 
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(Bonagura et al., 1998). RF in RA is produced by B cells which present in lymphoid 
follicles and germinal centers of inflamed synovium (Jones et al., 1984; Wernick et 
al., 1985) due to the rearrangements and somatic mutations of the germline genes 
(Firestein et al., 2012). It is shown that the abnormal regulation of spontaneous 
germinal centers promotes the formation of somatically mutated antibodies which 
could lead to autoimmunity (Domeier et al., 2017). 
 
However, RF is not unique to RA since it has also been detected in another type of 
autoimmune diseases, including systemic lupus erythematosus (SLE), primary 
Sjögren's syndrome and mixed connective tissue disease  (Nell et al., 2005; Šenolt et 
al., 2014). The increased incidence of RF positive reactions has been shown to be 
associated with aged individuals than in young individuals (Nell et al., 2005). 
Chronic infection is shown to be associated with a high prevalence of RF and it is 
reported to be more frequent and severe in aged persons (Gavazzi and Krause, 2002). 
RF is known to be sensitive but lacks specificity (Wahab et al., 2013). The sensitivity 
and specificity of RF range between 25-95% and 31-95%, respectively (Avouac et 
al., 2006).  
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1.2.6 (b)    Anti-citrullinated protein antibodies (ACPA) 
Citrullination is a post-translational modification of arginine by deimination 
(Klareskog et al., 2008; Suzuki et al., 2007). The conversion of arginine to 
citrulline is catalyzed by a group of calcium dependent, a peptidylarginine-
deiminase (PAD) enzyme consisting of five isoforms in mammals, PAD1-4 and 
PAD6 (Suzuki et al., 2007; Vossenaar et al., 2004a). The functions of PAD1s in 
normal immune responses is not certain; citrullination of some chemokines can 
decrease activity, and modification of histones can regulate gene expression in 
stressed cells (Firestein et al., 2012).  
 
Citrullination activated by calcium influx can occur as a normal part of cell 
apoptosis (Asaga et al., 1998). It has been shown that increased citrullination was 
first found in the lining and sublining cells in the joints of RA patients (Baeten et 
al., 2001). Citrullinated proteins have been detected in inflamed tissues in different 
types of arthritis (Vossenaar et al., 2004b), including  lungs, extra-articular sites in 
RA, human brain, as well as inflamed muscle and lymphoid organs (Bongartz et al., 
2007; Klareskog et al., 2006; Makrygiannakis et al., 2006; Nicholas and Whitaker, 
2002). 
 
Citrullination is known to play a role in terminal epithelial differentiation which 
occurs in tissues such as hair and skin (György et al., 2006). Meanwhile, in the 
nucleus, citrullination involves in epigenetic regulation (Wang et al., 2004). 
Citrullination also involved in host defence mechanism and fight against pathogens 
(Li et al., 2010). 
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Anti-citrullinated protein antibodies (ACPA) have been identified as sensitive and 
specific markers in RA (Klareskog et al., 2008), which establish superiority over 
RF in the diagnosis of RA. ACPA has been added as one of the criteria for the ACR 
classification for RA diagnosis (Aletaha et al., 2010). It has been hypothesized that 
induction of ACPA in RA patients occurs in the lungs or gingiva (Klareskog et al., 
2006; Nesse et al., 2012). This finding has been confirmed with another study 
(Janssen et al., 2015) which showed that the presence of IgG anti-CCP associated 
with bronchiectasis, and demonstrated to exhibit borderline significant trend with 
periodontis. 
 
ACPA can be detected several years before the onset of RA clinical symptoms 
(Koivula et al., 2007). They have been demonstrated to be present in 70-90% of 
established cases of RA with high disease specificity (90-95%) (Schellekens et al., 
2000; Suzuki et al., 2009). Furthermore, they are likely rare to be found in other 
diseases or in healthy individuals (Song and Kang, 2010). ACPA seropositivity is 
significantly associated with older RA patients (p<0.001) (Alpizar-Rodriguez et al., 
2017). Furthermore, a large population-based study consisting of 40136 RA cases 
in Netherlands demonstrated that the presence of ACPA is associated with several 
factors including older age, smoking, female gender and joint involvement (van 
Zanten et al., 2017). 
 
ACPA have been found to mediate the activation of osteoclasts which associate 
with the systemic bone loss in RA (Llorente et al., 2017). Therefore, it is 
recommended for RA patients with higher level of ACPA to undergo bone 
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examinations and be aggressively treated with disease modifying anti-rheumatic 
drugs (DMARDs) (Orsolini et al., 2017). 
 
ACPA can be detected using the first-generation of the cyclic citrullinated peptides 
(CCP), second-generation CCP (CCP2) or third-generation CCP (CCP3) (Trouw 
and Mahler, 2012). CCP test relies on peptide derived from the filaggrin protein 
(Schellekens et al., 1998), whereas the CCP2 and CCP3 tests rely on artificial 
peptides (Kessenbrock et al., 2007; Levesque et al., 2009). The formation of 
filaggrin occurs in the later stages of epithelial cells differentiation during the 
keratinization (Kuhn et al., 2006). The filaggrin is stored in the keratohyalin 
granules and cornified epithelium (Hoet et al., 1991; Simon et al., 1993).  
 
Anti-CCP is shown to be an independent marker for radiological damage and 
disease progression in RA (Forslind et al., 2004). Another study (Ji et al., 2017) 
demonstrated that the detection of bone erosion is independently associated with 
the presence of anti-CCP in RA patients indicating that the radiographic 
progression could provide little-added value in the early diagnosis of RA when anti-
CCP antibodies are absent. The high specificity of anti-CCP antibodies in RA (Lee 
and Schur, 2003) further support the importance of citrullination and the clinical 
utility of ACPA for the early diagnosis of RA (Schellekens et al., 2000).  
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1.2.6 (c) Additional autoantibodies 
There are many other autoantibodies that have been found in RA, which can 
be potential biomarkers to improve the diagnosis and prognosis of RA (Verheul et 
al., 2015a). Other autoantibodies against posttranslational modifications have also 
been identified, which are the autoantibodies directed against the PAD4. Anti-PAD4 
antibodies detected to be present in 22-45% of RA patients and 14% of SLE patients 
(Halvorsen et al., 2008; Zhao et al., 2008). It is described that anti-PAD4 antibodies 
are cross-reacts with anti-PAD3 antibodies, however, it is interesting that the cross-
reactivity is associated with severe radiological damage (Darrah et al., 2013). 
 
Another type of autoantibody is anti-RA33, directed against an antigen of 33 kDa, 
which binds to both unmodified and citrullinated heterogeneous nuclear protein 
(Verheul et al., 2015a). It has been identified that RA33 is citrullinated in the joint of 
RA patients and shown to be the target of the autoantibodies (anti-RA33) response 
(Konig et al., 2016b). Anti-Ra33 have been detected in RA patients with the 
sensitivity and specificity of 32% and 90-96%, respectively (Hassfeld et al., 1989). 
Interestingly, anti-Ra33 antibodies are associated with mild disease development in 
patients, which could serve as a prognostic marker (Nell et al., 2005). 
 
Anti-mutated citrullinated vimentin (anti-MCV) antibodies have been detected in 
early RA with the sensitivity and specificity of 64% and 97%, respectively 
(Rojanasantikul et al., 2014). A recent meta-analysis consisting of 12 studies among 
RA patients (n=2003), demonstrated a higher sensitivity of anti-MCV (68.6%) than 
anti-CCP (61.7%), however, anti-MCV specificity (94.2%) is lower than anti-CCP 
(97.1%) in the diagnosis of RA (Lee et al., 2015). 
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1.2.7    Assessment of disease activity 
Currently, disease activity in RA patients is monitored using a series of 
surrogate marker of inflammation consisting of functional disability, visual analog 
scales, joint involvement, and the acute phase reactants including erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) (Fransen et al., 2002; Wolfe 
et al., 2001). To ensure that therapy is effective, frequent clinical assessments are 
needed (Grigor et al., 2004). 
 
1.2.7 (a)    Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP) 
The acute-phase reactants, ESR and CRP are the most frequently used 
biological markers to assess disease activity in RA that appear to be equally useful 
and reliable as a monitoring test in the management of RA patients (Osei-Bimpong et 
al., 2007). It is demonstrated that there is an association between the increasing 
levels of ESR and CRP with the involvement of large joints and/or more joints in RA 
patients (Shimada et al., 2017). 
 
ESR values associated with disease activity in RA and therefore useful for 
monitoring therapeutic response (Lane and Gravel Jr, 2002). In addition, ESR is 
shown to be able to predict prognosis in patients diagnose with multiple myeloma 
indicating that ESR is an independent prognostic marker in disease (Alexandrakis et 
al., 2003). Furthermore, elevated values of ESR and CRP are considered a predictor 
factor in a diagnosis of pneumonia (Hopstaken et al., 2003). 
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CRP is synthesized by hepatocytes (Okamura et al., 1990) and the increased levels of 
CRP detectable in sera of patients are associated with various forms of acute and 
chronic inflammatory conditions (Young et al., 1991). The levels of CRP have been 
shown to be significantly correlated with disease activity, radiographic progression 
and response to therapy (Åman et al., 2000; Nakamura, 2000; Plant et al., 2000).  
 
CRP is known to be a specific marker of inflammation for assessment of disease 
activity since the hepatic synthesis of CRP is associated with the effects of 
inflammatory cytokines on the liver (Jansen et al., 2000). The severity of the 
inflammatory response measured by CRP has been demonstrated to be associated 
with the presence of atherosclerosis in RA patients (Gonzalez-Gay et al., 2005). 
Furthermore, RA patients with extra-articular manifestations shown to have higher 
levels of CRP (Turesson et al., 2007). The high levels of CRP associated with the 
progression of joint destruction in RA patients (Nawata et al., 2016). 
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1.2.7 (b)    Disease activity score 28 (DAS28) 
The advancement in therapy has improved the prognosis of RA patients. 
However, such therapies have high treatment costs and contribute to adverse 
reactions that pose an economic burden which directly impacts the health care 
system (Doan et al., 2006). The disease activity score (DAS) incorporates the 44-
joint counts, the visual analog score for pain reported by the patient, and the levels of 
ESR. The DAS has been described to be a sensitive and specific tool to assess 
disease activity in RA (Van der Heijde et al., 1990).  
 
Disease activity score-28 (DAS28) is the simplified version of the DAS that has been 
developed because of the greater number of joint counts in the original DAS are 
time-consuming (Castrejon et al., 2008). It is recommended to perform DAS28 as it 
is accurately measured disease activity in RA patients, sensitive to change, 
discriminate between states of remission, low, moderate and high disease activity, 
and feasible to perform at the healthcare centre (Anderson et al., 2012). 
 
It is demonstrated that high disease activity associated with lower functional 
capacities (Jansen et al., 2000). Although DAS28-CRP is also available, the DAS28 
is frequently used the ESR. However, a previous study demonstrated that DAS28-
CRP and DAS28-ESR were significantly correlated in Japanese cohort (Inoue et al., 
2007). It has been validated that both measures are necessary and useful for the 
disease activity assessment in RA patients (Wells et al., 2009). The modified version 
of DAS28 has been established to assess disease activity when the acute phase 
reactant values including ESR and CRP are not available, and it is decsribed as a 
sensitive tool to discriminate between disease states (Bentley et al., 2010). 
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1.2.7 (c)    Health Assessment Questionnaire (HAQ) 
The key to successful management of RA is to reduce the impact of the 
disease on patients’ lives and therefore improves the quality of life (Pollard et al., 
2005). It is known that RA and other rheumatic diseases associate with functional 
disability. The health assessment questionnaire (HAQ), established in 1980 is the 
first instruments to measure health status evaluated with patients’ self-reported 
outcomes (Fries et al., 1980).  
 
This established traditional approach have become one of the main measures for 
evaluation of health-related quality of life. HAQ has been established as an effective 
and sensitive tool to measure health status based on the evidence of its use over the 
past few decades in various settings. A recent study demonstrated that HAQ score is 
an independent predictor of severe progression in patients with an earlier stage of RA 
(Joo et al., 2017). 
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1.2.8    Treatment of RA 
Improved understanding of the pathogenesis of RA has led to the 
development of wide variety of RA treatments. The goal of treatment is to treat RA 
aggressively in early diagnosis since this could efficiently improve the physical 
function and quality of life (Schoels et al., 2010). Patients with early RA that have 
been provided with aggressive treatment shown to have less radiographic progression 
(Albers et al., 2001). Furthermore, it is shown that irreversible joint damage can be 
prevented if the patients are treated early in diagnosis especially during the first 
months of the disease (Bukhari et al., 2003) which suggests that the start of disease-
modifying antirheumatic drug (DMARD) therapy is associated with disease severity. 
 
The possible treatment option for RA is either the combination of DMARDs or the 
biologic DMARDs such as tumor necrosis factor-alpha (TNF-α) inhibitors (Fiehn 
and Kruger, 2016). The most frequently used drug for treating RA is methotrexate 
(MTX) which significantly improved the physical function and quality of life 
(Lopez-Olivo et al., 2014). MTX is shown to be involved in immune activity 
regulation and could reduce the damage of cartilage and bone (Hawtree et al., 2013).  
 
Furthermore, over the last decades, anti-TNF-α-targeted biologic agents known to 
have well-established effectiveness (Taylor and Feldmann, 2009).  TNF-α is a pro-
inflammatory cytokine responsible for the joint destruction in RA (Jenkins et al., 
2002). Studies utilizing anti-TNF-α agents demonstrate that they can reduce and 
control the disease progression in RA patients (Lipsky et al., 2000) which probably 
involves the suppression of osteoclast in the joint lesions (Redlich et al., 2002), 
resulting in improves physical function. RA patients achieve reduced disease activity 
